东方生物
(688298)
| 流通市值：52.21亿 | | | 总市值：52.21亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 657,613,863.02 | 418,235,233.09 | 182,922,481.69 | 820,157,331.67 |
| 营业收入 | 657,613,863.02 | 418,235,233.09 | 182,922,481.69 | 820,157,331.67 |
| 二、营业总成本 | 1,015,757,409.45 | 624,188,833.28 | 286,548,849.54 | 1,002,299,363.55 |
| 营业成本 | 429,479,876.84 | 269,301,346.85 | 123,745,857.61 | 467,402,664.29 |
| 税金及附加 | 5,126,317.49 | 3,088,599 | 1,174,324.79 | 15,068,503.02 |
| 销售费用 | 115,645,578.78 | 72,500,539.19 | 34,733,181.24 | 162,190,807.32 |
| 管理费用 | 301,544,840.3 | 204,636,205.23 | 90,024,520.84 | 372,357,302.08 |
| 研发费用 | 209,881,229.54 | 146,302,173.83 | 71,964,517.95 | 260,861,479.83 |
| 财务费用 | -45,920,433.5 | -71,640,030.82 | -35,093,552.89 | -275,581,392.99 |
| 其中:利息费用 | 14,332,103.62 | 10,259,896.71 | 3,502,978.11 | 18,120,027.97 |
| 其中:利息收入 | 83,735,447.92 | 71,646,394.71 | 43,053,339.92 | 207,669,151.14 |
| 加:公允价值变动收益 | 15,159,826.64 | 15,460,200.59 | 28,146,030.43 | -8,989,798.01 |
| 加:投资收益 | 70,757,363.61 | 42,503,594.04 | 15,278,250.54 | 42,014,305.37 |
| 资产处置收益 | 904,167.89 | -55,152.15 | 6,357.94 | -178,965.39 |
| 资产减值损失(新) | -16,640,365.02 | -9,024,879.15 | -3,250,750.11 | -236,508,701.39 |
| 信用减值损失(新) | 419,628.48 | -6,479,045.03 | -4,688,959.56 | -27,533,764.17 |
| 其他收益 | 4,996,672.21 | 3,764,476.46 | 680,696.18 | 29,504,295.15 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -282,546,252.62 | -159,784,405.43 | -67,454,742.43 | -383,834,660.32 |
| 加:营业外收入 | 6,887,356.75 | 3,667,750.26 | 16,204.61 | 4,211,085.85 |
| 减:营业外支出 | 2,028,129.64 | 1,333,238.16 | 678,704.45 | 24,603,155.94 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -277,687,025.51 | -157,449,893.33 | -68,117,242.27 | -404,226,730.41 |
| 减:所得税费用 | -3,459,475.91 | 2,594,118.89 | 1,838,041.47 | 14,042,100.02 |
| 六、净利润 | -274,227,549.6 | -160,044,012.22 | -69,955,283.74 | -418,268,830.43 |
| 持续经营净利润 | -274,227,549.6 | -160,044,012.22 | -69,955,283.74 | -418,268,830.43 |
| 终止经营净利润 | - | - | 0 | - |
| 归属于母公司股东的净利润 | -262,156,256.43 | -151,607,488.56 | -67,353,495.4 | -397,583,595.27 |
| 少数股东损益 | -12,071,293.17 | -8,436,523.66 | -2,601,788.34 | -20,685,235.16 |
| (一)基本每股收益 | -1.32 | -0.76 | -0.33 | -1.97 |
| (二)稀释每股收益 | -1.32 | -0.76 | -0.33 | -1.97 |
| 八、其他综合收益 | -17,554,233.08 | 2,568,899.2 | -8,352,902.11 | 14,107,016.69 |
| 归属于母公司股东的其他综合收益 | -17,554,233.08 | 2,568,899.2 | -8,352,902.11 | 14,107,016.69 |
| 九、综合收益总额 | -291,781,782.68 | -157,475,113.02 | -78,308,185.85 | -404,161,813.74 |
| 归属于母公司股东的综合收益总额 | -279,710,489.51 | -149,038,589.36 | -75,706,397.51 | -383,476,578.58 |
| 归属于少数股东的综合收益总额 | -12,071,293.17 | -8,436,523.66 | -2,601,788.34 | -20,685,235.16 |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |